Press Releases
-
NEW DATA ON CELLVIZIO PRESENTED AT DDW 2013 SUGGESTS THAT OPTICAL BIOPSIES MAY HELP CONFIRM AND RULE OUT PANCREATIC CYSTIC TUMORS*
ORLANDO (May 22, 2013) – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that optical biopsies using a microscope so tiny it fits through a small needle show clear cellular-level images inside pancreatic cysts, which could assist physicians in the diagnosis of pancreatic cystic tumors and help patients with benign cysts avoid unnecessary surgery, according to new data presented at Digestive Disease Week 2013, which concludes here today. Download the PDF
22/05/2013
-
FDA GRANTS MAUNA KEA TECHNOLOGIES 510(k) CLEARANCE TO MARKET AQ-FLEX™19 MINIPROBE FOR FINE NEEDLE ASPIRATION PROCEDURES
PARIS, April 30, 2013 – Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the AQ-‐FlexTM 19 miniprobe to provide real-‐time optical biopsies during endoscopic ultrasound-‐guided fine needle aspiration (EUSFNA) procedures in the digestive tract. This represents the sixth U.S. regulatory clearance for Mauna Kea Technologies’ Cellvizio or one of its dedicated miniprobes, which already obtained the CE mark in Europe. Download the PDF
30/04/2013
-
MAUNA KEA TECHNOLOGIES ANNOUNCES HIGHLIGHTS OF 5th ANNUAL INTERNATIONAL CONFERENCE OF CELLVIZIO® USERS (ICCU)
Mauna Kea Technologies today announced highlights from the 5th Annual International Conference of Cellvizio Users (ICCU) held in Versailles, France, from April 5 to 7. Over 200 international optical biopsy experts – a 70% increase in attendance over the 2012 meeting – representing 17 countries and a variety of specialties including digestive endoscopy, pulmonology, urology, surgery, otorhinolaryngology, pathology and pre-clinical research gathered to review and discuss the lates research and impact of optical biopsy on clinical care. Download the PDF
23/04/2013
-
MAUNA KEA TECHNOLOGIES REPORTS FIRST QUARTER 2013 SALES UP 11% TO €1.8m
PARIS (April 16, 2013) - Mauna Kea Technologies (NYSE Euronext: MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced its sales for the first quarter of the year ended March 31, 2013. Q1 2013 sales growth: 11% Sales grew by 11% year-over-year in the first quarter of 2013. Clinical sales (Cellvizio® sales to hospitals and clinics) moved up 16% to €1,440k, while preclinical sales (Cellvizio® sales to preclinical research laboratories) receded by 7% to €344k. Sales of Cellvizio® to hospitals and clinics, the company’s key target market, generated 81% of total revenue for the quarter, while preclinical sales accounted for 19%. The breakdown by product type shows that equipment sales edged down by 3% to €1,163k. Sales of consumables (miniprobes) advanced by 27% to €427k. Sales of services more than doubled, rising by 168% to €193k. Download the PDF
16/04/2013
-
MAUNA KEA TECHNOLOGIES REPORTS FIRST SALE OF CELLVIZIO® IN CHINA TO RENOWNED CHINESE OPTICAL BIOPSY PIONEER
PARIS (April 10, 2013) – Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced today that the first Cellvizio system was sold in China, one of the fastest growing, largest medical device markets in the world. Yan-Qing Li, MD, Professor of Gastroenterology at Shandong University, Qilu Hospital, a pioneer in the optical biopsy field in China and a prolific researcher on applications of endomicroscopy, will be a key resource for the education efforts in China. Download the PDF
10/04/2013
-
MAUNA KEA TECHNOLOGIES REPORTS FULL-YEAR 2012 RESULTS IN LINE WITH EXPECTATIONS
PARIS (March 26, 2013) – Mauna Kea Technologies (NYSE Euronext : MKEA, FR0010609263), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, today announced its full financial results for the 12 months ended December 31, 2012. Download the PDF
26/03/2013
-
LEADING USA PULMONOLOGISTS TO INVESTIGATE IMPACT OF MAUNA KEA TECHNOLOGIES’ CELLVIZIO ON LUNG CANCER DIAGNOSIS
PARIS (March 21, 2013) – Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, announced today that it has launched a registry study to determine the impact of Cellvizio optical biopsies on the diagnosis of lung cancer, the leading cause of cancer death in the world. Previous studies have shown that Cellvizio’s real-time, cellular-level views of distal lung tissue extend the reach and improve the diagnostic accuracy of bronchoscopy procedures, reducing the need to repeat invasive, expensive diagnostic tests. Download the PDF
22/03/2013
-
MAUNA KEA TECHNOLOGIES ANNOUNCES NEW STUDY SHOWS OPTICAL BIOPSY IS MORE ACCURATE THAN CONVENTIONAL ENDOSCOPIC BIOPSY IN DETECTING STOMACH CANCER
PARIS (March 14, 2013) – Mauna Kea Technologies (NYSE Euronext: MKEA), leader in the optical biopsy market and developer of Cellvizio®, the fastest way to see cancer, reported a new study showing that a Cellvizio optical biopsy can overcome the limitations of standard tissue biopsies in accurately diagnosing cancerous stomach tumors. The study was completed at the Soonchunhyang University Hospital Gastrointestinal Cancer Center in Seoul, Korea. The study findingsi were published online in the March Issue of Gastrointestinal Endoscopy. Download the PDF
14/03/2013
-
28/01/2013
Cellvizio featured in 9news.com : World's smallest microscope finds cancer faster
St. Anthony Hospital is the first hospital in Colorado to use the new advanced-imaging technology, called Cellvizio, with at-risk patients during standard endoscopy and colonoscopy procedures as well as the pancreatic and bile duct cancer detection procedure. Cellvizio allows physicians to view internal tissues cell-by-cell to pinpoint cancerous and pre-cancerous tissue more efficiently than current procedures. Dr. Matt Reveille says the new technology helps doctors respond once they identify dangerous tissue.more
-
26/11/2012
Cellvizio in the Sioux Falls Business Journal
Fantastic article by Sanford Hospital in the Sioux Falls Business Journal. "This can change the practice of medicine,” said Dr. Muslim Atiq, a gastroenterologist at Sanford. “The whole key is to find cancer before cancer occurs. To find it very early makes a big difference.”more
See all news
-
18/09/2013
WMIC Meeting 2013 Savannah
The World Molecular Imaging Congress is organized by the joint efforts of the “World Molecular Imaging Society – WMIS“, the “European Society for Molecular Imaging – ESMI” and the “Federation of Asian Societies for Molecular Imaging – FASMI“. The WMIC is led by the senior academic and industry professionals who have widely recognized expertise in molecular imaging. The scientific sessions held at the conference cover a broad spectrum of basic and translational sciences (pre-clinical to clinical) forming a Discovery-to-Delivery (D2D) process that helps facilitate academic and industrial partnerships. Through innovation, our goal is to optimize the D2D efforts leading to new medical and molecular imaging discoveries, greater linkages between research and market outcomes, and significant improvements in healthcare. Comme visit us and discover Cellvizio Dual Band for translational research!more
See all events
-
07/05/2013
Cellvizio News, May 2013
FDA grants Mauna Kea Technologies 510(k) clearance to market AQ-Flex™19 miniprobe for fine needle aspiration procedures Mauna Kea Technologies announced that the U.S. Food and Drug Administration (FDA) has cleared the AQ‐Flex™ 19 miniprobe to provide real‐time optical biopsies during endoscopic ultrasound‐guided fine needle aspiration (EUSFNA) procedures in the digestive tract. This represents the sixth U.S. regulatory clearance for Mauna Kea Technologies’ Cellvizio on one of its dedicated miniprobes, which already obtained the CE mark in Europe.more
See all newsletters
-
17/06/2013
CELLVIZIO DAY : TRAINING WORKSHOP AT PAOLI CALMETTES INSTITUTE - MARSEILLE, FRANCE
Acquire a basic understanding of how the Cellvizio system works, and learn how to interpret Cellvizio images of the esophagus, bile duc and colon. Live cases will be observed and the latest clinical data and case studies will be analyzed.
See all training opportunities
